Non-Alcoholic Steatohepatitis (NASH) accounted for a 6.3% share of the global clinical trials within the Gastrointestinal therapy area in 2020, registering an increase of 3.0% when compared with the last ten-year average of 3.3% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for NASH
Industry sponsored trials held an 80.5% share of all the clinical trials for NASH indication in 2020, registering an increase of 32.0% when compared with the ten-year average of 48.5%. Non-industry sponsored trials accounted for a 19.5% share in 2020, marking a decrease of 32.0% over the ten-year average of 51.5%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored NASH trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNorth America was the top region for industry sponsored NASH trials, accounting for a 53.4% share in 2020, when compared with the five-year average of 69.4% and ten-year average of 53.2%.
Asia-Pacific was at the second position with a 44.8% share in 2020, over the five-year average of 31.9% and ten-year average of 28.5%, followed by Europe with a 22.4% share in 2020, as against five-year and ten-year averages of 33.5% and 42.4% respectively.
Middle East and Africa stood fourth with an 8.6% share in 2020, compared with the five-year average of 11.2% and ten-year average of 13.6%, followed by South and Central America with a 6.9% share in 2020, over five-year and ten-year averages of 6.6% and 3.3% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for industry sponsored NASH trials, accounting for a 51.7% share in 2020, as against the five-year average of 67.2% and ten-year average of 52.1%.
China held a 19.0% share in 2020, over the five-year average of 4.8% and ten-year average of 2.4%, followed by Australia with a 17.2% share in 2020, compared with the five-year and ten-year averages of 15.6% and 11.9% respectively.
Canada held a 12.1% share in 2020, as against the five-year average of 14.5% and ten-year average of 11.2%.
Japan held a 12.1% share in 2020, over the five-year and ten-year averages of 7.4% and 5.7% respectively.
Top regions of non-industry sponsored NASH trials
Asia-Pacific was the top region for non-industry sponsored NASH trials, accounting for a 52.9% share in 2020 when compared with the five-year average of 39.4% and ten-year average of 36.0%.
Middle East and Africa was at the second position with a 17.6% share in 2020, over the five-year and ten-year averages of 26.3% and 25.9% respectively, followed by North America with a 17.6% share in 2020, as against the five-year average of 23.4% and ten-year average of 19.7%.
Europe stood at the fourth position with an 11.8% share in 2020, compared with the five-year average of 10.9% and ten-year average of 18.4%, followed by South and Central America with a 0.0% share in 2020, over the five-year and ten-year averages of 1.1% and 0.5% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored NASH trials, accounting for a 23.5% share in 2020, as against the five-year average of 16.4% and ten-year average of 11.4%.
Iran held a 17.6% share in 2020, over the five-year average of 21.2% and ten-year average of 20.4%, followed by South Korea with a 17.6% share, compared with the five-year and ten-year averages of 2.1% and 1.0% respectively.
The US held a 17.6% share in 2020, as against the five-year average of 18.6% and ten-year average of 15.3%.
India held a 5.9% share in 2020, over the five-year average of 4.5% and ten-year average of 5.0%.
Phase I trials lead industry sponsored clinical trials for NASH in 2020
Phase I trials held a 57.1% share of industry sponsored clinical trials for NASH in 2020, over the five-year average of 48.2% and ten-year average of 44.1%.
Phase II trials held a 37.1% share in 2020, as against the five-year average of 45.6% and ten-year average of 48.4%. Phase III trials held a 5.7% share in 2020, compared with the five-year and ten-year averages of 5.2% and 6.9% respectively.
Phase IV trials held a 0.0% share in 2020, over the five-year average of 1.1% and ten-year average of 0.6%.
Phase II trials lead non-industry sponsored clinical trials for NASH in 2020
Phase II trials held a 58.8% share of non-industry sponsored clinical trials for NASH in 2020, over the five-year average of 61.2% and ten-year average of 66.8%.
Phase I trials held a 23.5% share in 2020, as against the five-year average of 12.7% and ten-year average of 7.1%. Phase III trials held an 11.8% share, compared with the five-year and ten-year averages of 14.1% and 15.1% respectively.
Phase IV trials held a 5.9% share in 2020, over the five-year average of 12.0% and ten-year average of 11.0%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
